FIELD: biotechnology.
SUBSTANCE: disclosed is a bispecific antibody containing a first antigen-binding site capable of binding factor VII (a), and a second antigen-binding site capable of binding TLT-1. Also disclosed is a pharmaceutical composition containing said antibodies, which is used in the treatment of coagulopathy.
EFFECT: invention enables to obtain bispecific antibodies with improved pharmaceutical properties.
11 cl, 37 tbl, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| TNF RECEPTOR-BINDING AGONISTS | 2016 |
|
RU2821343C2 |
| NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
